【瞩目】方盛制药猛攻中药1类新药，4100亿市场掀热潮

米内网2025-08-06

精彩内容近日，CDE官网显示，方盛制药申报的中药1.1类新药紫英颗粒获得临床试验默示许可，用于治疗盆腔炎性疾病后遗症-慢性盆腔痛（湿热瘀结证）。今年以来，国内已有36款中药1类新药获批临床，方盛制药、康缘药业、盈科瑞等大丰收。米内网数据显示，2024年中国三大终端六大市场（统计范围详见本文末）中成药销售额超过4100亿元。紫英颗粒是方盛制药开发的一款中药1.1类创新药，具有清热解毒、除湿化浊、化瘀...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2557732252?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-06 16:06","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2557732252","market":"sh","top_or_hot":-1,"title":"【瞩目】方盛制药猛攻中药1类新药，4100亿市场掀热潮","media":"米内网","content":"<div>\n<p>精彩内容近日，CDE官网显示，方盛制药申报的中药1.1类新药紫英颗粒获得临床试验默示许可，用于治疗盆腔炎性疾病后遗症-慢性盆腔痛（湿热瘀结证）。今年以来，国内已有36款中药1类新药获批临床，方盛制药、康缘药业、盈科瑞等大丰收。米内网数据显示，2024年中国三大终端六大市场（统计范围详见本文末）中成药销售额超过4100亿元。紫英颗粒是方盛制药开发的一款中药1.1类创新药，具有清热解毒、除湿化浊、化瘀...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806162347a6d6228b&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【瞩目】方盛制药猛攻中药1类新药，4100亿市场掀热潮</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【瞩目】方盛制药猛攻中药1类新药，4100亿市场掀热潮\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-06 16:06 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806162347a6d6228b&s=b><strong>米内网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>精彩内容近日，CDE官网显示，方盛制药申报的中药1.1类新药紫英颗粒获得临床试验默示许可，用于治疗盆腔炎性疾病后遗症-慢性盆腔痛（湿热瘀结证）。今年以来，国内已有36款中药1类新药获批临床，方盛制药、康缘药业、盈科瑞等大丰收。米内网数据显示，2024年中国三大终端六大市场（统计范围详见本文末）中成药销售额超过4100亿元。紫英颗粒是方盛制药开发的一款中药1.1类创新药，具有清热解毒、除湿化浊、化瘀...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806162347a6d6228b&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"603998","symbol_name":"方盛制药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806162347a6d6228b&s=b","article_id":"2557732252","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806162347a6d6228b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2557732252","pubTimestamp":1754467611,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"精彩内容近日，CDE官网显示，方盛制药申报的中药1.1类新药紫英颗粒获得临床试验默示许可，用于治疗盆腔炎性疾病后遗症-慢性盆腔痛。今年以来，国内已有36款中药1类新药获批临床，方盛制药、康缘药业、盈科瑞等大丰收。紫英颗粒是方盛制药开发的一款中药1.1类创新药，具有清热解毒、除湿化浊、化瘀散结的功效。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600557":"康缘药业","603998":"方盛制药","BK0060":"抗癌","BK0188":"融资融券","BK0028":"国家队","BK0239":"医药制造"},"translate_title":"[Attention] Fangsheng Pharmaceutical attacks Class 1 new Chinese medicine drugs, and the 410 billion market sets off a boom","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600557":0.9,"603998":1},"content_text":"精彩内容近日，CDE官网显示，方盛制药申报的中药1.1类新药紫英颗粒获得临床试验默示许可，用于治疗盆腔炎性疾病后遗症-慢性盆腔痛（湿热瘀结证）。今年以来，国内已有36款中药1类新药获批临床，方盛制药、康缘药业、盈科瑞等大丰收。米内网数据显示，2024年中国三大终端六大市场（统计范围详见本文末）中成药销售额超过4100亿元。紫英颗粒是方盛制药开发的一款中药1.1类创新药，具有清热解毒、除湿化浊、化瘀散结的功效。其临床申请于今年5月获得CDE承办受理，并于近日顺利获批临床，用于盆腔炎性疾病后遗症-慢性盆腔痛（湿热瘀结证），症见下腹隐痛、腰骶胀痛、带下量多，色黄质稠、低热起伏、经期腹痛加重、胸闷纳呆、口干、大便溏或便秘、小便黄赤者。今年以来，方盛制药已有3款中药1.1类创新药提交IND，分别为香芩解热颗粒（已获批临床）、紫英颗粒（已获批临床）及妇科止血消痛颗粒，其中紫英颗粒、妇科止血消痛颗粒均为妇科用药。米内网数据显示，2024年中国三大终端六大市场妇科中成药销售额超过200亿元，同比增长约4%。今年以来方盛制药申报临床的中药新药来源：米内网中国申报进度（MED）数据库方盛制药始创于2002年，以“创新中药研发”为核心竞争力。近年来公司不断加大研发投入与力度，围绕妇科、儿科、心脑血管、消化、呼吸等领域布局新药开发。据不完全统计，目前方盛制药有6款中药创新药在国内处于申请临床及以上阶段（不含已有批文品种），其中健胃祛痛微丸处于III期临床，蛭龙通络片、益气消瘤颗粒均处于II期临床。近年来，随着中医药利好政策频繁出台，国内药企开展中药新药项目的热情高涨。今年以来，国内有36款中药1类新药（含1.1类及1.2类，不含非制剂产品）获批临床，集中在妇科用药、神经系统疾病用药、心脑血管疾病用药、骨骼肌肉系统疾病用药等治疗领域。今年以来获批临床的中药1类新药来源：米内网中国申报进度（MED）数据库从申报企业看，5家药企均有2个品种在列，包括方盛制药的紫英颗粒及香芩解热颗粒，康缘药业的连参更年颗粒及固本消疹颗粒，广药集团的LBZ-18口服乳及BYS30颗粒，苏州玉森新药开发的苓仙颗粒及仙茜颗粒，北京盈科瑞医药的金桔余甘含片及小儿苓龙早熟颗粒。资料来源：米内网数据库、CDE官网等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至8月6日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2557732252","isCrawlerRequest":true}